Valion Bio, Inc. (VBIO) company profile
Close on Nov 13, 2026Market cap $2.20MP/E –Yield –
About Valion Bio
Pharmaceutical Preparations, SIC 2834
Tivic Health Systems, Inc. operates within the health technology and biopharmaceutical sectors. The company identifies business activities across Biopharma and contract development and manufacturing organization (CDMO) segments, while classifying its Clearup operations within discontinued operations. Through licensing agreements, it engages in biopharmaceutical drug development, including milestones for acute radiation syndrome therapies and neutropenia applications, alongside CDMO-related services.
The company maintains its principal executive offices in San Antonio, Texas, with additional historical facility lease commitments and operations cited in Hayward, California. Its corporate infrastructure and commercial development activities also reference leases for mammalian, microbial, and office facilities. Its common shares trade publicly on the Nasdaq Stock Market.
Summary of the business section of Valion Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Valion Bio, Inc.
- Headquarters
- San Antonio, TX
- Address
- 1305 E. Houston Street, Building 1, Suite 311 78205
- Phone
- (888) 276-6888
- Website
- valionbio.com
- Employees
- 52, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Rosenberg Rich Baker Berman, P.A., Somerset, New Jersey
Stock & identifiers
- Ticker
- VBIO
- Former tickers
- TIVC until May 4, 2026
- Exchange
- Nasdaq
- IPO date
- Nov 12, 2021
- Shares outstanding
- 22M, Aug 13, 2026
- Public float
- $4.00M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-25 reverse, Aug 31, 2026; 1-for-17 reverse, Mar 7, 2025; 1-for-100 reverse, Aug 23, 2023
- SEC CIK
- 1787740
- CUSIP
- 918942202
- ISIN
- US9189422028
- FIGI
- BBG00PT2YC04
- Share class FIGI
- BBG00PT2YC13
- EIN
- 81-4016391
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Dean Zikria | Interim CEO, Director | – |
| Michael K. Handley | Chief Executive Officer, Director | 11,030 |
| Jennifer Ernst | Chief Executive Officer, Director | 37,953 |
| Lisa G. Wolf | COO & CFO | 27 |
| Melinda Lackey | General Counsel & SVP of Legal | – |
| Blake Gurfein | Chief Scientific Officer | 119,979 |
| Jared David Malbin | Director | – |
| Thomas Jensen | Director | – |
| Sheryle Bolton | Director | 10,000 |
| Christina Rizopoulos Valauri | Director | 19,000 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 12, 2021
- Offer price
- $5.00
- Securities offered
- 3,000,000
- Gross proceeds
- $15.00M
- Exchange
- Nasdaq
- First trading day
- Nov 11, 2021
- First-day close
- $5.19+3.8%
- Lock-up ends (est.)
- May 10, 2022
“The initial public offering price of our shares of common stock is $5.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 52 full-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?